Glimicet-MV 1 Tablet SR is a fixed-dose combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma concentrations and improved patient compliance. Glimicet-MV 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Caution is advised in patients at risk of lactic acidosis or hypoglycemia. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination offers a comprehensive approach targeting multiple pathophysiological defects in type 2 diabetes, optimizing glycemic management.